Podcasts about ADT

Heather Dunn, Chief People Officer at Brex, joined us on The Modern People Leader. We talked about Brex's rapid acquisition by Capital One and how Heather led through diligence, communication, and integration.----  Sponsor Links:

Patsy Mangan joined us on The Modern People Leader. We talked about Scribd Flex, why flexibility only works when it is paired with clarity and accountability, and why Scribd needed the GRIT Performance framework.----  Sponsor Links:

Brandon Roberts, leader of Talent Strategy and Workforce Transformation at ServiceNow, joined us on The Modern People Leader. We talked about how ServiceNow is redesigning HR for the AI era, why every role needs to be mapped for AI impact, and more.----  Sponsor Links:

Jessica Zwaan joined us on The Modern People Leader. We talked about her first four months at Leapsome, why HR needs to operate more like a product team, and how AI agents, forward-deployed engineers, and flexible HR systems could reshape the future of people operations.----  Sponsor Links:

Molly Graham, Host of WorkLife Podcast & Co-Founder of Glue Club and The Guild, joined us on The Modern People Leader. We talked about career emergence, why fear is slowing down AI adoption at work, and why the future of HR will depend on leaders who can create clarity, curiosity, accountability, and better management habits for both people and AI agents.----  Sponsor Links:

Kate Connor, Chief Operating Officer at Moxie Communications Group, joined us on The Modern People Leader. We talked about how Moxie is adopting AI safely, why leaders should automate low-judgment work first, and how to embed AI into the culture without replacing human creativity, judgment, and relationships. ----  Sponsor Links:

Davida Lindsay-Bell, Chief People Officer at Hanna Andersson, joined us on The Modern People Leader. We talked about why AI transformation needs to start with people, how Hanna Andersson operationalized psychological safety, and why trust, learning, and intelligent failure are the foundation for lasting change.----  Sponsor Links:

Brian and Tom invite Neha Vapiwala, a Radiation Oncologist, to discuss areas of consensus and controversy from the PROTEUS trial of ADT +/- apalutamide in high-risk localized prostate cancer.

In this episode, UROONCO PCa chief editor Dr. Giancarlo Marra interviews Prof. Mary-Ellen Taplin from Dana–Farber Cancer Institute in the United States, on the results of the PROTEUS trial. The PROTEUS trial is a phase 3, double-blind, placebo-controlled trial evaluating the benefit of adding apalutamide to standard androgen deprivation therapy (ADT) in men with high-risk, localised prostate cancer undergoing radical prostatectomy.They discuss the rationale, patient selection and the results of this trial (dual primary endpoint), as well as the impact of the results on clinical practice. Prof. Taplin concludes in the take-home messages that this trial has illustrated the progress being made in regard to preventing and delaying relapse.To know more on this trial, read the abstract with expert commentary by UROONCO PCa associate editor Assoc. Prof. Pawel Rajwa. For more updates on prostate cancer, please visit our educational platform UROONCO PCa.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

Laura Fuentes, CHRO at Hilton, joined us on The Modern People Leader. We talked about Hilton's hospitality mindset, why great leaders should operate like great hosts, and how Hilton scales culture, listening, recognition, and purpose across more than 500,000 team members.----  Sponsor Links:

AUA2026: Contemporary Management of Advanced Prostate Cancer: Guidelines and Beyond CME Available: https://cme.auanet.org/URL/26DC040ONL LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Identify appropriate use of genetic testing, genetic counseling as well as somatic testing. 2. Describe appropriate use of treatment-related to specific genetic alterations. 3. Identify appropriate combination therapy with ADT plus novel androgen receptor pathway inhibitors and chemotherapy. Early treatment intensification as well as appropriate de intensification will be discussed in mHSCPC. 4. Describe the treatments for non-metastatic CRPC and oncologic outcomes based on AUA/SUO and NCCN Guidelines. 5. Counsel patients on available treatment options for CRPC as well as combination therapy and sequencing based on AUA/SUO and NCCN Guidelines. ACKNOWLEDGEMENTS: Support provided by independent educational grants from: Astellas Lantheus Medical Imaging Novartis Pharmaceuticals Corporation Pfizer, Inc

For decades, men with high-risk prostate cancer have routinely been told they need 18 to 36 months of androgen deprivation therapy (ADT) alongside radiation.But what if 12 months is enough?In this episode of the Dr. Geo Prostate Podcast, Dr. Geo Espinosa welcomes internationally recognized radiation oncologist Dr. Dan Spratt, Chair of Radiation Oncology at University Hospitals/Case Western Reserve University, to discuss groundbreaking research that could change how advanced prostate cancer is treated.Together they explore the latest MARCAP consortium data suggesting many men may receive the same cancer control with significantly less hormone therapy—potentially reducing years of unnecessary side effects while maintaining excellent outcomes. They also discuss how physicians personalize treatment decisions, the growing role of artificial intelligence with Artera AI, and why the future of prostate cancer treatment may involve doing less, not more.If you or someone you love is facing radiation therapy for prostate cancer, this episode provides one of the most important conversations happening in prostate cancer care today.What You'll Learn✔ Why 2-3 years of ADT may not be necessary for many patients✔ The new evidence supporting approximately 12 months of hormone therapy✔ Why longer hormone therapy can permanently affect testosterone recovery✔ How physicians balance cancer control with quality of life✔ The difference between NCCN guidelines and individualized patient care✔ Which patients may still benefit from longer hormone therapy✔ How AI (Artera AI) is helping personalize prostate cancer treatment✔ Why prostate cancer care is shifting toward treatment de-intensification✔ The future of precision medicine in radiation oncologyEpisode Timestamps00:00 Introduction01:30 Meet Dr Dan Spratt02:22 Why ADT Lasts Years05:42 How ADT Helps Radiation08:49 Personalizing ADT Duration12:39 Guidelines and Real World Use18:03 Who Needs Long Term ADT21:13 Artera AI Explained23:19 Old Data and Modern Outcomes27:28 De Intensification Future31:33 Biomarkers for Urologists33:57 Choosing Artera vs Decipher37:28 Final Takeaways and OutroKey Discussion PointsNew MARCAP consortium analysis on ADT durationRadiation sensitivity and androgen deprivationWhy many men never fully recover testosterone after prolonged ADTBalancing survival outcomes with quality of lifeShared decision-making between physician and patientGenomic classifiers including DecipherAI biomarkers and Artera AIPersonalized radiation oncologyModern imaging and PSMA PETDe-intensifying prostate cancer treatmentPrecision medicine in localized prostate cancerThe future of individualized prostate cancer careResources Mentioned• MARCAP Consortium research on androgen deprivation therapy duration• NCCN Prostate Cancer Guidelines (discussed throughout the episode)• Artera AI clinical decision support platform (discussion)• Decipher genomic classifier• PSMA PET imaging• MRI-guided prostate cancer staging___________________________________

Jessie Zwaan, author of Purpose and Work and Built for People, joined us on The Modern People Leader. We talked about why the old purpose-at-work narrative is breaking, how people relate to work through jobs, careers, and callings, and why HR leaders need to rethink how they build meaning into work.----  Sponsor Links:

We've been told for decades that giving testosterone to a man with prostate cancer is like throwing gasoline on a fire. But what if, in the right context, it actually acts as the extinguisher?” It sounds like medical heresy, yet this is the foundation of Bipolar Androgen Therapy (BAT). Imagine a treatment that intentionally cycles your hormones from extreme highs to extreme lows to "overload" cancer cells and reset their sensitivity to medicine.In this episode, we sit down with a true pioneer of this paradigm shift: Dr. Michael Schweizer. An Associate Professor at the Fred Hutchinson Cancer Center and a key architect behind the original BAT trials at Johns Hopkins, Dr. Schweizer is the scientist moving the bar for men with advanced, castrate-resistant disease. We're moving past the fear-based dogma to look at the clinical data that proves supraphysiologic testosterone isn't just a quality-of-life booster—it's a sophisticated weapon against resistant tumors.In this episode, you'll learn:The "Hormone Shock" Mechanism: How flooding the body with 1,500+ ng/dL of testosterone causes "mitotic catastrophe" in cancer cells adapted to low-androgen environments.The Resensitization Secret: Why cycling BAT can actually "reset" your cancer, making drugs like Enzalutamide work again after they've failed.Precision Selection: Which specific genetic mutations (like TP53) might predict who becomes an "exceptional responder" to high-dose testosterone.The Sequential Strategy: Why the order of your treatments—BAT first, then RPIs—could potentially extend survival by nearly 10 months.⏱️ Chapters00:00 Introduction: Can Testosterone Treat Prostate Cancer? 02:00 The surprising origin of Bipolar Androgen Therapy (BAT) 04:10 ⭐ Stop & Watch: Why Charles Huggins hinted at this decades ago 07:10 Why ordinary testosterone therapy failed—and BAT didn't 08:20 ⭐ Stop & Watch: The BAT protocol explained (400 mg every 28 days) 10:00 Why BAT is only used in castration-resistant prostate cancer 14:05 ⭐ Stop & Watch: The TRANSFORMER trial—did BAT actually work? 16:20 ⭐ Stop & Watch: How BAT may make failed treatments work again 20:30 ⭐ Stop & Watch: If testosterone isn't the enemy...why do we suppress it? 22:10 ⭐ Must Watch: The biology that completely changes how we think about testosterone 24:10 How BAT damages cancer DNA 26:30 BAT, quality of life, and survival—what the evidence really shows 30:00 ⭐ Stop & Watch: The sequencing strategy that could add months of cancer control 31:30 Which patients may respond best to BAT? 33:20 ⭐ Must Watch: Why every advanced prostate cancer patient should consider genetic testing 36:00 Can someone on ADT simply start testosterone? 40:00 Where BAT fits among today's prostate cancer treatments 43:00 ⭐ Stop & Watch: BAT + Lutetium PSMA—the next frontier 45:00 How to find BAT clinical trials 47:00 Should hormone therapy ever be stopped? 53:00 Final thoughts____________________________________

Daniel Bay, Chief People Officer at Underdog, joined us on The Modern People Leader. We talked about why HR teams in hypergrowth should stop copying big-company playbooks, how Underdog invests deeply in manager coaching, and why impact matters more than activity.----  Sponsor Links:

AUA2026: Focus on: ADT in the Modern Era - Balancing Cancer Control and Cardiovascular Safety CME Available: https://cme.auanet.org/URL/FOCUS265ONL LEARNING OBJECTIVES: After participating in this CME activity, participants will be able to: 1. Integrate cardiovascular (CV) risk assessment into ADT initiation by applying key findings from the REVELUTION-1 trial to identify patients at elevated risk for atherosclerosis and MACE. 2. Compare and apply the CV safety profiles of LHRH agonists versus GnRH receptor antagonists to guide personalized ADT selection in patients with varying CV risk. 3. Implement streamlined monitoring strategies for men on oral ADT, including testosterone levels, lipid and blood pressure evaluation, and surveillance for early CV risk indicators. 4. Collaborate with cardiology and primary care to optimize statin use and coordinate CV risk-reduction strategies for prostate cancer patients receiving ADT. 5. Strengthen shared decision making and adherence by incorporating discussions of oncologic benefit, CV risk, and mitigation strategies into routine oral ADT counseling and follow-up. ACKNOWLEDGEMENTS: Support provided by independent educational grants from: Pfizer, Inc Sumitomo Pharma America, Inc.

In this episode of The Dr. Haley Show, Dr. Michael Haley speaks with Michael Bovarnick, founder of The Prostate Education Project, about his personal journey through prostate cancer, recurrence, treatment decisions, and the mission that grew out of his experience.Michael shares what it was like to hear the words “you have prostate cancer,” why education became such an important part of his journey, and how clear information can help reduce fear for men, spouses, caregivers, and families facing prostate cancer.The conversation covers PSA testing, Gleason scores, prostate cancer recurrence after prostate removal, androgen deprivation therapy (ADT), ADT side effects, ADT holidays, intimacy and relationship challenges, and the importance of having a spouse, partner, or loved one present during medical appointments.Dr. Haley and Michael also discuss Michael's long history with Haley Nutrition's Aloe Vera Gel Health Drink as part of his personal wellness routine. Aloe vera is not presented as a cancer cure. Instead, this conversation focuses on education, supportive wellness, patient empowerment, and asking better questions when navigating serious health decisions.Michael's closing message is simple and powerful:Knowledge reduces fear.Understanding builds confidence.Education empowers patients.Episode Resources:The Prostate Education Projecthttps://theprostateeducationproject.org/Haley Nutrition Aloe Vera Gel Health Drinkhttps://haleynutrition.com/Dr. Haley Show Noteshttps://drhaley.com/Haley Nutritionhttps://haleynutrition.com/Episode Highlights:00:00 PSA testing and false positives00:39 Meet Michael Bovarnick of The Prostate Education Project02:50 How Dr. Haley and Michael first connected03:14 Michael's prostate cancer diagnosis and aloe vera story05:37 Important disclaimer about aloe vera and cancer08:05 Why prostate cancer can return after prostate removal10:54 Life today after prostate cancer recurrence12:18 Prostate cancer awareness and rising diagnosis rates13:36 PSA testing, screening, and Dr. Haley's personal story16:59 Hearing the words “you have prostate cancer”18:46 Intimacy, relationships, and emotional challenges23:10 What doctors explain — and what patients may miss26:22 Advice for newly diagnosed men in the panic phase28:33 PSA, Gleason score, and treatment decisions31:06 What is ADT? Androgen deprivation therapy explained32:45 ADT side effects doctors may not fully prepare you for34:51 Why you should bring a partner to appointments36:39 What is an ADT holiday?39:27 PSA testing advice for men over 4040:36 Urinary symptoms, enlarged prostate, and getting checked42:49 Prostate cancer symptoms beyond urinary problems43:52 Exercise, diet, bone health, and muscle health during ADT45:00 Exploring TheProstateEducationProject.org46:47 Spanish-language resources and community outreach48:32 Final thoughts: Knowledge reduces fearMedical Disclaimer:This podcast is for educational purposes only and is not medical advice. The information shared in this episode should not be used to diagnose, treat, cure, or prevent any disease. Always consult your physician or qualified healthcare provider regarding PSA testing, prostate cancer screening, diagnosis, medications, supplements, treatment options, or any health-related decisions.Aloe vera is discussed in this episode as part of Michael Bovarnick's personal wellness routine and experience. It is not presented as a treatment or cure for prostate cancer.About Michael Bovarnick:Michael Bovarnick is the founder of The Prostate Education Project, a growing educational resource created to help prostate cancer patients, spouses, caregivers, and families better understand the prostate cancer journey. His work focuses on clear explanations, practical tools, lived experience, and helping people know what questions to ask when facing diagnosis, treatment decisions, side effects, recurrence, and recovery.About Dr. Michael Haley:Dr. Michael Haley is the host of The Dr. Haley Show and founder of Haley Nutrition, known for producing raw, inner-leaf Aloe Vera Gel Health Drink and other natural wellness products. Through the podcast, Dr. Haley explores natural health, patient education, practical wellness strategies, and conversations that help listeners take a more informed role in their health journey.

Nichole Viviani, Chief People, Culture and Change Officer at Global Payments, joined us on The Modern People Leader. We talked about why culture makes or breaks M&A, how Global Payments aligned 27,000 people through “goals before roles,” and why leaders need to over-communicate through uncertainty.----  Sponsor Links:

Courtney Kolar, Chief People Officer at Neighborly, joined us on The Modern People Leader. We talked about how she helped build an HR function from a three-person team into a 40-person people organization, the People Services 2020 roadmap that created the foundation for scale, and why every company should operate as if it needs to be IPO ready.----  Sponsor Links:

Sunaina Lobo, Chief People Officer at Omnissa, joined us on The Modern People Leader. We talked about why the HR-IT partnership is becoming critical in the AI era, how Omnissa is approaching AI transformation with a small but mighty team, and what it takes to build an AI-first culture while maintaining trust and engagement.----  Sponsor Links:

Featuring a slide presentation and related discussion from Dr Rana R McKay, including the following topics: Overview of the current landscape of prostate cancer (0:00) Mechanism of action of androgen deprivation therapy (ADT) (3:51) Findings from the Phase III HERO study evaluating relugolix versus leuprolide for advanced prostate cancer (7:18) Real-world evidence regarding the use of relugolix (12:27) Adverse event profile associated with ADT (18:34) Case: A man in his early 70s with metastatic hormone-sensitive prostate cancer who receives ADT at various timepoints of treatment and is currently on relugolix (21:46) Case: A man in his early 60s with high-risk locally advanced prostate cancer who receives various androgen receptor pathway inhibitors in addition to relugolix (28:06) CME information and select publications

Patricia Frost, Chief People and Places Officer at Seagate, joined us on The Modern People Leader. We talked about her military-to-CPO journey, how Seagate built Talent Link to unlock internal mobility, and what it looks like to democratize AI across a global workforce.----  Sponsor Links:

Alan Morton experienced symptoms associated with prostate cancer, but it was some time before he sought medical attention.  Dating back to his teens, he had had a subpar urine flow, but in his sixties, he began to see blood in his urine.  He thought it might be a urinary tract infection, but when nothing had changed six months later, he contacted his doctor.  After various scans, a digital rectal exam and a biopsy, Alan was told he had Stage 3B prostate cancer.  It was later determined the cancer had metastasized to his pelvic and was re-diagnosed as Stage 4 Incurable.  He was placed on a hormone regimen including the injection of a drug called decapeptyl.  Alan said the side effects were awful, including fatigue, loss of muscle mass, weight gain and a severe loss of testosterone.  He suspects he will be on the hormone regimen for the rest of his life, but Alan Morton calls himself a prostate cancer endurant.  He still engages in hiking, and despite the handicaps, seeks to live life to the fullest.   It was in 2023 when Alan began to pass blood in his urine.  He didn't think this development was worth sharing with his wife or his doctor.  However, his wife saw what she thought was dark urine when Alan went to the bathroom and forgot to flush.  He told her he was passing blood and she immediately made a doctor's appointment for him.   Alan submitted to a digital rectal exam and provided a urine sample.  Although he thought the sample was "crystal clear," the doctor said the sample included "microscopic blood."  He was called in for another appointment, provided another blood sample.  From that and a biopsy, he received a diagnosis of Stage 3B prostate cancer.    Because of neck trauma stemming from a long ago auto accident, Alan could have his prostate removed.  His care team concluded the only available treatment option would be a hormone regimen, starting with androgen deprivation therapy, or ADT.  He said the effect it had on his body was awful.  They included fatigue, severe loss of testosterone, hair loss, plus weight gain in various places, among them, his breasts.  He was subsequently prescribed the injection of a drug, decapeptyl, and a pill called bucalutamide, designed to stop the growth of the tumor.  The ADT regimen stopped in October 2024, but the following month he began to pass blood again.  To make matters worse, his PSA, once at 0.037, rose sharply to 6.39 in April 2026.  Alan underwent a bone scan that indicated his cancer had spread to his pelvis.  He is back on ADT and expects he will be for the rest of his life.   Alan says his urinary function is outstanding but would rate his sexual function at something like 20 to 30 percent of what it was pre-diagnosis.   Alan Morton does not call himself a survivor of cancer, but rather an endurant.  He knows given his diagnosis and his hormone regimen, he is at reduced capacity, but aspires to live a full, rich life.   Additional Resources:   Support Group:   Fans for the Cure: https://www.fansforthecure.org      

Kate Railton, Chief People Officer at Mejuri, joined us on The Modern People Leader. We talked about how Mejuri transitioned from e-commerce into retail, why they've decided to flatten the organization, and the business review cadences and operating model that allow them to move faster.----  Sponsor Links:

Still using androgen deprivation therapy (ADT) alone for patients with metastatic hormone-sensitive prostate cancer (mHSPC)? Learn the latest on optimizing outcomes with combination therapies. Credit available for this activity expires: 6/25/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/new-era-mhspc-treatment-evaluating-emerging-doublet-and-2026a1000kt7?ecd=bdc_podcast_libsyn_mscpedu

Daniel moderated a live panel at Running Remote 2026 with Carmen Amara (Yelp), Brandon Sammut (Zapier), and Vinícius Coelho (Time Doctor) to discuss how AI is reshaping leadership, management, and career growth. ----  Sponsor Links:

In this compelling episode of the Dr. Geo Prostate Podcast, Dr. Geo sits down with internationally renowned exercise oncology pioneer Professor Robert Newton to explore the groundbreaking science behind exercise as medicine for cancer.Inspired by his father's battle with prostate cancer, Professor Newton has spent decades researching how targeted exercise can improve treatment outcomes, preserve muscle mass, strengthen immune function, reduce treatment side effects, and potentially slow cancer progression. Together, Dr. Geo and Professor Newton discuss why muscle is far more than a movement organ—it functions as a powerful endocrine organ that releases cancer-fighting compounds known as myokines.The conversation dives deep into exercise intensity, resistance training, chemotherapy and radiation timing, wearable technology, exercise "dosing," and the landmark Phase III clinical trial that demonstrated exercise can significantly improve survival outcomes in cancer patients. They also discuss practical strategies for overcoming fear of the gym, maintaining muscle during androgen deprivation therapy (ADT), and why sitting all day may undermine your health even if you exercise regularly.Whether you're living with prostate cancer, supporting a loved one, or simply interested in maximizing your healthspan, this episode provides actionable, science-backed strategies to help you move from surviving to thrivingEpisode Timestamps00:00 Introduction & Guest Welcome 03:00 Rob Newton's Father & Origin Story 09:30 Exercise as the #1 Anti-Cancer Tool 17:00 Landmark Exercise Oncology Trial 20:00 Exercise as Medicine 26:00 Resistance Training Intensity Explained 35:30 Exercise Before Radiation & Chemotherapy 40:00 Exercise Timing Around Treatment 47:00 Myokines: Muscle as Medicine 52:00 NEAT & Daily Movement 58:00 Final Takeaways & Closing ThoughtsResources MentionedMy Exercise Medicine for Cancer by Professor Robert NewtonExercise Medicine Research InstituteNew England Journal of Medicine Exercise Oncology TrialAmerican Society of Clinical Oncology (ASCO) Researc___________________________________

Welcome to this episode of Oncology Brothers, where we dived into the latest advancements in GU malignancies! We welcomed esteemed guests Dr. Brian Rini and Dr. Thomas Powles, both GU medical oncologists and co-hosts of the Uromigos podcast.   In this episode, we discussed key studies presented at ASCO 2026 that are set to change clinical practice in prostate, kidney and bladder cancer, and recent FDA approvals in the GU space: PROTEUS:  trial comparing ADT monotherapy to apalutamide plus ADT in high-risk localized prostate cancer. We explored its findings, implications, and the ongoing debate surrounding its control arm. TALAPRO-3 Study: impact of PARP inhibitors combined with enzalutamide in metastatic castration-sensitive prostate cancer with homologous recombination repair (HRR) mutations. We discussed the nuances of HRR mutations and their clinical significance. CAPITELLO-281: insights into the recent approval of this AKT inhibitor for metastatic castration-sensitive prostate cancer with PTEN loss, based on the CAPItello-281 study. EV-302 update: combination of EV-pembrolizumab still maintains the doubling of survival benefit with longterm follow up. POTOMAC: durvalumab + BCG induction therapy for high-risk non-muscle invasive bladder cancer (NMIBC) could be a choice for a selected patient population. LITESPARK-022: The new approval of belzutifan with pembrolizumab in the adjuvant setting, discussing its efficacy and the importance of patient selection.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o ' Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966   Follow us on social media: X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/   Throughout the episode, we emphasized the importance of balancing treatment benefits with potential adverse events, as well as the need for shared decision-making in clinical practice. #GUOncology, #ASCO2026, #ProstateCancer, #BladderCancer, #RenalCellCarcinoma, #OncologyBrothers

In this EAU Podcast episode, Ass. Prof. Giancarlo Marra (IT), Prof. Derya Tilki (DE) and Prof. Philip Cornford (IE) discuss the latest updates in the 2026 EAU Guidelines on Prostate Cancer.They explore changes in risk stratification, the evolving role of enzalutamide plus ADT in high-risk disease, and emerging diagnostic technologies such as micro-ultrasound and NeuroSAFE. The conversation also highlights advances in personalised treatment approaches for metastatic hormone-sensitive prostate cancer, including BRCA and PTEN-targeted strategies.In addition, the speakers emphasise the growing importance of supportive care, bone protection, and managing long-term treatment-related side effects to improve patient outcomes.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

Ray'n Terry, Chief People Officer at MOO, joined us on The Modern People Leader to discuss why AI should create more space for humanity at work instead of simply increasing productivity. We talked about balancing business performance with employee wellbeing, rethinking performance management in an AI-powered world, and why leaders must intentionally help people reclaim time, creativity, and connection.----  Sponsor Links:

Amy Reichanadter, Chief People Officer at Databricks, joined us on The Modern People Leader to discuss her upskilling journey throughout her career, creating consumer-grade employee experiences, and leading through rapid technological change. ----  Sponsor Links:

Gustavo Guanabara volta ao ADT para comentar o que achou da WWDC26, além das novidades do Google for Brasil 2026.

Dennis Rader was the council president of Christ Lutheran Church in Park City, Kansas, on the morning of February 25, 2005. The Wichita Police Department was, at the same moment, on its way to arrest him. The thing that had identified him as BTK was a metadata trace from a Microsoft Word document he had saved to a church computer in his role as council president.He had volunteered for the council. He had volunteered to print agendas. He had risen through the ranks to council president, the visible layperson at a small congregation. He had been doing both jobs for years. The killing and the church. The Cub Scout pack and the typed letters to the press. The compliance officer truck and the kits in the garage.In the third chapter of host Tony Brueski's five-part Hidden Killers investigation, every official role Dennis Rader chose for himself gets examined for what it actually gave him. The ADT alarm installer job that put him inside hundreds of Wichita homes legally during the most active years of his killing. The Cub Scout pack leader role that put him in front of children while teaching them the family of knots that had been showing up at his crime scenes since 1974. The Lutheran council seat that gave him community standing and, eventually, identified him to investigators. The Sedgwick County Zoning Appeals seat. The Animal Control Advisory Board. The compliance officer truck.This episode also walks through Misty King's story. A Park City divorcee who fled the state with her two children after Dennis Rader, in his city role, made her life unlivable.This is the third uncomfortable truth of the series. Dennis Rader did not hide despite his costumes. He hid inside them.END LINKSJoin Our SubStack For AD-FREE ADVANCE EPISODES & EXTRAS!: https://hiddenkillers.substack.com/ Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/channel/UC8-vxmbhTxxG10sO1izODJg?sub_confirmation=1 Instagram https://www.instagram.com/hiddenkillerspod/ Facebook https://www.facebook.com/hiddenkillerspod/ Tik-Tok https://www.tiktok.com/@hiddenkillerspod X Twitter https://x.com/TrueCrimePodDISCLAIMERThis publication contains commentary and opinion based on publicly available information. All individuals are presumed innocent until proven guilty in a court of law. Nothing published here should be taken as a statement of fact, health or legal advice.HASHTAGS#BTK #DennisRader #ChristLutheran #ChurchCouncil #HiddenKillers #TrueCrime #SerialKillers #ParkCity #ColdCase #UncomfortableTruths

Cameron Price, Head of People & Talent at Medium, joined us on The Modern People Leader to discuss how people teams can lead AI change management through trust, curiosity, and human-centered design. We talked about AI fluency, balancing innovation with authenticity, measuring employee sentiment around AI adoption, and why humans-first leadership matters more than ever. ----  Sponsor Links:

For half a century, the BTK Killer story has been told the way Dennis Rader wanted it told. Factor X. The Minotaur. The BTK brand. Every term that has anchored his mythology came from a typewriter in his own kitchen in Park City, Kansas. Every term was his.In this first chapter of a five-part investigation from True Crime Today, host Tony Brueski sets the version of Dennis Rader that documentaries have repeated for forty-seven years next to the actual investigative file. The two don't match.The man who wrote the 1978 Factor X letter to KAKE-TV was a thirty-two-year-old husband and father. An alarm installer for ADT in Wichita. A student at Wichita State University working toward a degree in the administration of justice. He had taken courses on profiling. He knew what serial killers were supposed to sound like in the cultural imagination of the late seventies. He typed himself into the role.The press printed his words. The cops filed his words. The country read his words. And for nearly fifty years, when somebody has tried to explain Dennis Rader, they have explained him the way he wanted to be explained.This episode walks through the 1978 letter sentence by sentence. The literary references he borrowed from. The cultural figures he compared himself to. The contradictions inside the letter that read, in retrospect, less like the confession of a possessed killer and more like the audition tape of a man trying out for a role.The series will continue with the chase that didn't close, the official roles that made him invisible, the thirteen-year silence between his confirmed killings, and the floppy disk that ended his thirty-one years of getting away with it. Start here.END LINKSJoin Our SubStack For AD-FREE ADVANCE EPISODES & EXTRAS!: https://hiddenkillers.substack.com/ Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/channel/UC8-vxmbhTxxG10sO1izODJg?sub_confirmation=1 Instagram https://www.instagram.com/hiddenkillerspod/ Facebook https://www.facebook.com/hiddenkillerspod/ Tik-Tok https://www.tiktok.com/@hiddenkillerspod X Twitter https://x.com/TrueCrimePodDISCLAIMERThis publication contains commentary and opinion based on publicly available information. All individuals are presumed innocent until proven guilty in a court of law. Nothing published here should be taken as a statement of fact, health or legal advice.HASHTAGS#BTK #DennisRader #BTKKiller #TrueCrimeToday #FactorX #SerialKillers #Wichita #ParkCity #TrueCrime #ColdCase

Nir Leibovich, Product Executive at QuickBooks Workforce, joined us on The Modern People Leader to discuss why HR and finance teams struggle when data lives in silos and how unified systems create better business decisions. Downloadable PDF with top takeaways: https://modernpeopleleader.kit.com/episode306----  Sponsor Links:

Amy Schwartz, Chief People Officer at Wiz, joined us on The Modern People Leader. We talked about why HR alone can't create a high-performance culture, why relationships and influence matter more than HR systems, and why "picking up the trash" - a leadership philosophy she picked up working in casinos - has stuck with her ever since.----  Sponsor Links:

Laura Tomaino, Chief People Officer at Glooko, joined us on The Modern People Leader. We talked about why “People-First” leadership feels harder in 2026 and what it actually looks like to live up to that today.----  Sponsor Links:

In this episode, Andrew is joined by Jimmy Lin from ADT who shares the insider story behind ADT's new DIY-focused Blu system—an easy-to-install, smart security kit designed for the modern homeowner. We break down how ADT may leverage open standards like Matter and Z-Wave, aiming to unify the smart home ecosystem and finally bridge the gap between security and automation.You'll uncover:How ADT's innovative products like the new Live Light smart sign and color night-vision cameras empower homeowners to be proactive rather than reactive.The role of AI and sensor fusion, like Wi-Fi and activity zone detection, in predicting threats before they happen.Why a focus on privacy, seamless integration, and ease of use is transforming the DIY security market.The strategic move into open protocols to create a more connected, interoperable smart home landscape.What's next for ADT: The possibility of introducing scene automation, smart home triggers, and voice command support like Siri shortcuts to truly integrate security with daily life.Jimmy Lin is VP of Product Management at ADT, steering innovations that bridge the gap between trusted home security and intelligent automation. With extensive experience in consumer electronics and AI-powered products—from GoPro cameras to AR glasses—Jimmy brings a keen eye for transforming classic brands into future-ready powerhouses.This episode is packed with actionable insights and future trends that will shape your smart home strategy. Perfect for tech lovers, security pros, and anyone eager to stay ahead of the curve. Don't miss out—hit play now and discover how ADT is redefining what home security can be.Send me your smart home questions and recommendations with the hashtag #SmartHomeInsider. Tweet and follow your host at:@andrew_osu on Twitter@andrewohara941 on ThreadsEmail me hereSponsored by:Shopify: Sign up for a one-dollar-per-month trial period at shopify.com/homekit!Copilot Money:  Limited-time: Get two months free when you sign up at copilot.money/smarthome and use coupon code SMARTHOME!Smart Home Insider YouTube ChannelSubscribe to the Smart Home Insider YouTube Channel and watch our episodes every week! Click here to subscribe.Links from the showGovee TV Backlight 3Govee G25 Filament BulbBose Lifestyle LineupBlu by ADTThose interested in sponsoring the show can reach out to us at: andrew@appleinsider.com

Jevan Lenox, Chief People Officer at Writer, joined us on The Modern People Leader. We talked about why AI adoption alone is not enough, how companies can use “directed innovation” to drive real business outcomes with AI, and what high performance looks like in the AI era.----  Sponsor Links:

What if I told you that after focal therapy, a normal PSA and a clean MRI can still mean prostate cancer is hiding in plain sight?That's the moment in this conversation that makes you stop—and rethink everything you've been told about “success” after focal therapy.In this episode, we're joined by Abhinav Sidana, MD, MPH, Associate Professor of Urology and Director of Prostate Cancer at University of Chicago Medicine, a nationally recognized urologic oncologist, clinical trial leader, and one of the architects shaping the future of focal therapy. Dr. Sidana has trained at AIIMS, Johns Hopkins, NIH, and now leads one of the most rigorous focal therapy programs in the country—backed by over 100 peer-reviewed publications and multiple active clinical trials.This is not a sales pitch for focal therapy. It's a clear-eyed look at what works, what doesn't, and what we still get wrong.In this episode, you'll learn:✅ Why MRI made focal therapy possible—and why it can still miss clinically significant disease✅ How biopsy strategy—fusion, mapping, or transperineal—directly affects recurrence risk✅ Why PSA is an unreliable signal after focal therapy—and what actually predicts failure✅ How short-term ADT may expand focal therapy to larger or higher-risk tumorsIf you're a patient, clinician, or researcher navigating prostate cancer decisions, this episode will fundamentally sharpen how you think about focal therapy—and its limits.00:00 Can MRI and PSA Miss Significant Cancer After Focal Therapy?04:00 Who Is a Good Candidate for Focal Therapy?06:30 Mapping Biopsies vs MRI Fusion Biopsies09:30 Transperineal vs Transrectal Biopsies11:00 What Is IRE (NanoKnife)?14:30 Who Is NOT a Candidate for Focal Therapy?18:00 Vapor Therapy & TULSA Pro23:00 Should Doctors Use Multiple Focal Therapy Technologies?25:30 Can Higher-Risk Prostate Cancer Be Treated with Focal Therapy?34:00 Does the Type of Energy Matter?37:00 Combining ADT with Focal Therapy40:30 How Tumor Size Impacts Eligibility45:30 Why MRI and PSA Are Imperfect After Treatment49:30 What Is PSA Recurrence After Focal Therapy?53:30 The Future of MRI, AI, and Surveillance57:30 Do Patients Need Repeat Biopsies Forever?___________________________________

Kirsten Moorefield, Chief Strategy Officer & Co-Founder at Cloverleaf, Sarika Lamont, CPO at Vidyard, and Sarah Royer, Sr. Manager of People Ops at Nirvana Insurance, joined us on The Modern People Leader for a live discussion on AI coaching. We talked about what AI coaching actually means today, building these tools in-house versus buying, and why career growth will never be a perfect checklist.----  Sponsor Links:

Cara Brennan Allamano (Founder of PeopleTech Partners and former Chief People Officer at Lattice) and Jevan Lenox (Chief People Officer at Writer) joined Stephen at Fix Healthcare Live. They talked about the growing pressure on HR leaders and why modern people leaders need to rethink how they operate in a rapidly changing world.----  Sponsor Links:

Lindsay Jurist-Rosner, Co-Founder and CEO of Wellthy, and Stephan Dolling, AVP of Global Benefits & Well-being at Merck, joined us on The Modern People Leader. We talked about the rising pressures facing working families and what companies can do to support their employees that are caregivers.----  Sponsor Links:

Jessica Zwaan, VP People Strategy & Operations at Leapsome and author of Built For People, joined us for another MPL Build AMA. This time we talked about how to redesign your People team if you're running your team like a product team, why metrics like internal promotion retention matter more than traditional HR KPIs, and more.----  Sponsor Links:

Amin Palizban, Co-Founder & CEO of TopicFlow, joined us on The Modern People Leader. We talked about why managers are at a breaking point, how AI is transforming performance management, and what it takes to build AI-native people products that actually support managers in real time.----  Get the AI for Performance Management Toolkit: https://modernpeopleleader.kit.com/aiforperformanceSponsor Links:

We discuss a couple of big stories from the week where insiders made a big profit on the prediction markets. We've discussed Polymarket and Kalshi before, but the concerns are going mainstream. We've also got some other tech news and tips to get caught up on, so you can get out there and tech better. Watch on YouTube! - Notnerd.com and Notpicks.com INTRO (00:00) Social Media Marketing World (02:20) AirPods - One backup is none backup (04:35) MAIN TOPIC: I wouldn't bet on that (07:20) France investigates suspected tampering with weather sensors after Polymarket bets DOJ arrests soldier who made $400,000 betting on Maduro's removal https://polymarket.com/ DAVE'S PRO-TIP OF THE WEEK: iOS Photos quick tools access (16:35) JUST THE HEADLINES: (21:05) Fans angry over Pokemon Go champion's disqualification for allegedly shaking the table Study finds a third of new websites are AI-generated Mozilla uses Anthropic's Mythos to fix 271 bugs in Firefox Home security giant ADT data breach affects 5.5 million people Ping-pong robot Ace makes history by beating top-level human players BMW is one step closer to selling you a color-changing car America now has 70% more bookstores than in 2020, says bookshop.org founder TAKES: China blocks Meta's $2 billion takeover of AI startup Manus (24:20) 20,000 job cuts at Meta, Microsoft raise concern that AI-driven labor crisis is here (28:45) BONUS ODD TAKE: Livestream of the Big Bear bald eagle nest (31:40)

We're back for more listener dating dilemmas, and we cover everything. From texting gaps and gut feelings, to dating with kids (and narcissistic exes), intentional dating vs. playing it cool, and how to show interest without overdoing it.We also get into independent women being punished for their independence, overbearing moms, men trashing their exes, co-parenting with narcissists, and how to keep your nervous system regulated when dating (or divorce) dynamics get messy. Plus, dating your husband when you have kids, setting boundaries, and trusting patterns when someone shows you exactly who they are.A word from my sponsors:Upward - Download Upward. The dating app where faith and values meet.ADT - When every second counts, count on ADT. Visit adt.com or call 1-800-ADT-ASAP.Figs - Get 15% off your first order at wearfigs.com with the code FIGSRXLMNT - Right now LMNT is offering a free sample pack with any purchase, That's 8 single serving packets FREE with any LMNT order. This is a great way to try all 8 flavors or share LMNT with a friend. Get yours at DrinkLMNT.com/HONEST.Kahlua - Find Kahlúa Dunkin Caramel Swirl at retailers nationwide, including Walmart, Total Wine, Albertsons, Kroger, Ralphs, Safeway, BevMo, Publix, and more. Must be 21 or older to purchase. Please drink responsibly.IQBAR - Text HONEST to 64000 to get 20% off all IQBAR products, plus FREE shipping. Message and data rates may apply.Taylor Farms - Grab a Taylor Farms chopped salad kit. And get your salad together!For more Let's Be Honest, follow along at:@kristincavallari on Instagram@kristincavallari and @dearmedia on TikTokLet's Be Honest with Kristin Cavallari on YouTubeProduced by Dear Media.This episode may contain paid endorsements and advertisements for products and services. Individuals on the show may have a direct or indirect financial interest in products, or services referred to in this episode.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Listener dating dilemmas are back—and I'm always reminded how crazy it is out there. This episode is packed with your real-life dating questions, from men in relationships following (and liking) other women on social media, to ghosting, exclusivity gone wrong, and major red flags you should never ignore. We're talking social media behavior, emotional maturity, cheating in the honeymoon phase, and why liking photos is very different than just following.I also get into flirting (how to do it without overthinking), dating younger men, money in relationships, being “too loyal too fast,” and whether it's okay to have fun with the wrong ones while waiting for the right one. Plus, what it really means when someone won't talk about their past, why photos of an ex are an immediate no, and how to support a friend who keeps dating the same toxic type.A word from my sponsors:Nutrafol - See thicker, stronger, faster-growing hair with less shedding in just 3-6 months with Nutrafol. For a limited time, Nutrafol is offering our listeners $10 off your first month's subscription and free shipping when you go to Nutrafol.com and enter the promo code HONESTTaylor Farms - Grab a Taylor Farms chopped salad kit. And get your salad together!Upward - Download Upward. The dating app where faith and values meet.ADT - When every second counts, count on ADT. Visit adt.com or call 1-800-ADT-ASAP.Mill - Try Mill risk-free for 90 days and get $75 off at mill.com/HONEST and use code HONEST at checkout.Revolve - Shop at REVOLVE.com/HONEST and use code HONEST for 15% off your first order. #REVOLVEpartnerKahlua - Find Kahlúa Dunkin Caramel Swirl at retailers nationwide, including Walmart, Total Wine, Albertsons, Kroger, Ralphs, Safeway, BevMo, Publix, and more. Must be 21 or older to purchase. Please drink responsiblyFor more Let's Be Honest, follow along at:@kristincavallari on Instagram@kristincavallari and @dearmedia on TikTokLet's Be Honest with Kristin Cavallari on YouTubeProduced by Dear Media.This episode may contain paid endorsements and advertisements for products and services. Individuals on the show may have a direct or indirect financial interest in products, or services referred to in this episode.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This week, I'm joined by country music's most eligible bachelor, Tucker Wetmore. We talk about how a football injury changed the course of his life, what it was like moving to Nashville without knowing a single soul, and how one song completely flipped everything.A word from my sponsors:Netflix's Age of Attraction - Watch Age of Attraction Wednesdays starting March 11, only on NetflixTaylor Farms - Grab a Taylor Farms chopped salad kit. And get your salad together!ADT - When every second counts, count on ADT. Visit adt.com or call 1-800-ADT-ASAP.Bon Charge - Go to boncharge.com/HONEST and use coupon code HONEST to save 15%.Ritual - Save 25% on your first month at Ritual.com/BEHONESTFIGS - Get 15% off your first order at wearfigs.com with the code FIGSRXVivrelle - Go to www.vivrelle.com and apply for a membership today using referral code HONEST for your first month of membership free - the code will also allow you to skip the Vivrelle waitlist.For more Let's Be Honest, follow along at:@kristincavallari on Instagram@kristincavallari and @dearmedia on TikTokLet's Be Honest with Kristin Cavallari on YouTubeProduced by Dear Media.This episode may contain paid endorsements and advertisements for products and services. Individuals on the show may have a direct or indirect financial interest in products, or services referred to in this episode.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.